2,770$
1,09%
Echtzeit-Aktienkurs Eledon Pharmaceuticals Inc.
Bid:
Ask:
Echtzeit-Chart der Eledon Pharmaceuticals Inc. Aktie
Börsenkurse Eledon Pharmaceuticals Inc.
| Tradegate | - | - | - | - | 2,350€ | -1,26% |
| Börse Stuttgart | - | - | - | - | 2,360€ | 0,00% |
| Börse Frankfurt | - | - | - | - | 2,350€ | 2,17% |
| Echtzeit Euro | - | - | - | - | 2,350€ | -0,42% |
| Echtzeit USD | - | - | - | - | 2,759$ | 0,31% |
| USA | - | - | - | - | 2,750$ | 0,36% |
| Nasdaq | - | - | - | - | 2,770$ | 1,09% |
Fundamentaldaten der Eledon Pharmaceuticals Inc. Aktie
Aktuelle Geschäftsentwicklung
Sie benötigen die TraderFox Börsensoftware, um die aktuelle Geschäftsentwicklung einsehen zu können.
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2024 [USD] | - | -35,75 Mio. | -36,18 Mio. | -0,75 | - | - | - |
| 2023 [USD] | - | -116,54 Mio. | -116,54 Mio. | -4,73 | - | - | - |
| 2022 [USD] | - | -87,97 Mio. | -87,97 Mio. | -6,16 | - | - | - |
| 2021 [USD] | - | -36,86 Mio. | -34,51 Mio. | -2,33 | - | - | - |
| 2020 [USD] | - | -23,22 Mio. | -22,81 Mio. | -15,72 | - | - | - |
| 2019 [USD] | - | -16,01 Mio. | -16,01 Mio. | -24,43 | - | - | - |
| 2018 [USD] | - | -14,07 Mio. | -14,07 Mio. | -28,11 | - | - | - |
| 2017 [USD] | - | -13,12 Mio. | -10,78 Mio. | -41,40 | - | - | - |
| 2016 [USD] | - | -37,96 Mio. | -37,96 Mio. | 0,00 | - | - | - |
| 2015 [USD] | - | -45,09 Mio. | -45,09 Mio. | -325,62 | - | - | - |
| Die Multiples wie die KGVs werden mit der Bilanzwährung und dem Kurs des ausgewählten Börsenplatzes berechnet. Wählen Sie den Börsenplatz mit der Bilanzwährung aus, damit die Multiples korrekt sind. Die fundamentalen Daten werden von Facunda geliefert; Multiples werden mit dem aktuellen Kurs berechnet. | |||||||
Profil der Eledon Pharmaceuticals Inc. Aktie
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The firm’s compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential. The CD40L/CD40 pathway is recognized for its prominent role in immune regulation, making it a candidate for therapeutic intervention in transplant tolerance, autoimmune disease, and neuro-inflammation. The company is building upon a deep historical understanding of the CD40/CD40L pathway, as well as preclinical and Phase 1 data, to initiate up to four phase 2 clinical studies with AT-1501. Eledon Pharmaceuticals was founded on March 26, 2004 and is headquartered in Irvine, CA.